2. Dry Chemical Technology The biggest difference between “dry chemistry” and traditional “wet chemistry” (i.e., solution chemistry) is the media involved in the chemical reactions. In this method, the liqui..

Thermo Fisher and Biomobio Sign Strategic Agreement in Spatial Imaging Thermo Fisher Scientific and Biomobio have successfully concluded a strategic cooperation agreement for the EVOS S1000..

Fapon and KIVDA Sign Strategic Agreement to Deepen China-Korea IVD Collaboration On 23 May, Fapon Biotech signed a strategic cooperation agreement with the Korea In Vitro Diagnostics Associ..

Chinese President Xi Jinping arrived in Hanoi on Monday to pay a state visit to Vietnam.

AdvaMed and nine other healthcare organizations have continued to pressure the White House to exempt medical devices and critical supplies from the Trump administration’s ongoing tariff saga.

At the 7th China International Import Expo (CIIE), themed "New Era, Shared Future", representatives from 152 countries, regions, and organizations gathered for national and corporate exhibitions. On 8 November, Switze..

As of August 31, 2025, China has 83 publicly listed companies related to in vitro diagnostics (IVD), including 62 whose core business is IVD and 21 with IVD-related operations. Among the 62 core IVD companies, 59 have..

Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.

The U.S. Commerce Department said on Wednesday it has opened new national security investigations into the import of personal protective equipment, medical items, robotics and industrial machinery.

Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest’s provider clients that order lab testing from Quest will be able to directly order Shield through their existing Quest account and electronic health record (EHR). Quest provided healthcare connectivity solutions to approximately 650,000 clinician and hospital accounts last year. Quest’s provider clients will also be able to refer patients to Quest’s 2,000 patient service centers and 6,000 in-office phlebotomists for blood draws in the United States. In addition, Quest’s national commercial sales team will proactively educate primary care physicians and obstetricians and gynecologists about the test, accelerating awareness among Quest’s ordering providers. Shield is expected to be available for physician order through Quest in the first quarter of 2026.

Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, “Burning Rock”) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion diagnostic for AstraZeneca’s capivasertib has received Manufacturing and Marketing Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW).

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs.

The US Food and Drug Administration (FDA) issued finalized guidance on Monday outlining the criteria for authorizing emergency use of unapproved in vitro diagnostic tests (IVDs) during future public health emergencies.

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.

Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.